Adavosertib and Gemcitabine in Advanced Pancreatic

James Cleary, MD, PhD (Other)
Overall Status
Withdrawn ID
AstraZeneca (Industry), Lustgarten Foundation (Other), Stand Up To Cancer (Other)

Study Details

Study Description

Brief Summary

This study is being done to test the safety and effectiveness of combining Adavosertib and Gemcitabine in patients with pancreatic cancer.

The names of the study drugs involved in this study are:
  • Adavosertib

  • Gemcitabine

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

This is an open label, single arm phase 2 trial evaluating adavosertib combined with gemcitabine in platinum-resistant advanced pancreatic cancer.

Laboratory studies suggest that adavosertib and gemcitabine can impair the growth of cancers by interfering with the way cancer cells repair their DNA.

The U.S. Food and Drug Administration (FDA) has not approved adavosertib as a treatment for any disease. The U.S. Food and Drug Administration (FDA) has approved gemcitabine as a treatment option for pancreatic cancer.

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

It is expected that about 32 people will take part in this research study.

The Lustgarten Foundation for Pancreatic Research and Stand Up to Cancer are supporting this research study by providing funding to conduct the study. AstraZeneca, a pharmaceutical company, is supplying the study drug, Adavosertib.

Study Design

Study Type:
Actual Enrollment :
0 participants
Intervention Model:
Single Group Assignment
None (Open Label)
Primary Purpose:
Official Title:
Phase 2 Single Arm Trial Testing Adavosertib and Gemcitabine in Platinum-Resistant Advanced Pancreatic Adenocarcinoma
Anticipated Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Adavosertib and Gemcitabine

Participants will receive: Adavosertib 1x per day on days 2, 3, 9, 10, 16, and 17 of every 28 day study cycle. Gemcitabineon on days 1,8, and 15 of every 28-day cycle

Drug: Adavosertib
Taken Orally
Other Names:
  • AZD 1775
  • Drug: Gemcitabine
    Intravenous Infusion
    Other Names:
  • Gemzar
  • Outcome Measures

    Primary Outcome Measures

    1. Overall Response Rate (ORR) [Baseline and every 8 weeks during treatment until disease progression or unacceptable toxicity up to 2 years]

      The primary objective is the evaluation of the overall response rate (ORR) by RECIST 1.1 criteria. Objective response rate (ORR) is defined as the proportion of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.

    Secondary Outcome Measures

    1. Overall Survival (OS) [Every 8 weeks during treatment, followed for survival after treatment discontinuation up to 2 years]

      Overall Survival (OS) is based on the Kaplan-Meier method and is defined as the time from study entry to death or censored at date last known alive.

    2. Progression-free Survival (PFS) [Every 8 weeks during treatment, followed for survival after treatment discontinuation up to 2 years.]

      Progression-free Survival (PFS) is based on the Kaplan-Meier method and is defined as the duration of time from study entry to documented disease progression (PD) or death. Per RECIST 1.1 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions.

    3. Disease Control Rate (DCR) [Baseline and every 8 weeks during treatment until disease progression or unacceptable toxicity up to 2 years]

      Disease Control Rate (DCR) defined as stable disease for ≥16 weeks, confirmed complete response (CR), or confirmed partial response (PR). CR defined as Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters

    4. Incidence of Grade 3 or Higher Treatment-Related Toxicity [Assessed day 1, 2, 3, 8, 9, 10, 15 and 22 at cycle 1, also day 1, 8, 9 and 15 at cycle 2+, and off-treatment up to 2 years. Each cycle is 28 days.]

      Evaluation of the safety and tolerability of this combination in platinum-resistant pancreatic cancer patients as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. All grade 3 or higher adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv5 as reported on case report forms were counted. Incidence is the number of patients experiencing at least one treatment-related grade 3 or higher AE of any type during the time of observation.

    Eligibility Criteria


    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Accepts Healthy Volunteers:
    Inclusion Criteria:
    • Participants must have a histologically confirmed advanced pancreatic adenocarcinoma that is not curable with standard approaches based on the judgement of the treating investigator. Patients with metastatic pancreatic cancer and unresectable pancreatic cancer are eligible.

    • Patients must have progressed on a platinum-based regimen prior to enrolling on the trial.

    • Patients must have received no more than 1 prior lines of platinum-based chemotherapy in the metastatic setting. Therapy given in the adjuvant or neoadjuvant setting is counted as a prior therapy if it occurred less than 6 months before cancer recurrence or progression.

    • Age ≥ 18 years. As no dosing or adverse event data are currently available in participants < 18 years of age, children and adolescents are excluded from this study.

    • ECOG performance status of 0 or 1 (see Appendix A).

    • Participants must have adequate organ and marrow function as defined below:

    • Absolute neutrophil count ≥ 1,500/mm3

    • Platelets ≥ 100,000/mm3

    • Hemoglobin ≥ 9 g/dL

    • Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN); or total bilirubin ≤3.0 x ULN with direct bilirubin WNL in patients with documented Gilbert's Syndrome.

    • Alanine aminotransferase (ALT) and ≤ 3 × institutional ULN; or ≤ 5 × institutional aspartate aminotransferase (AST) ULN if known hepatic metastases

    • Albumin ≥ 2.7 g/dL

    • Serum creatinine ≤ 1.5 × institutional ULN -OR-

    • Creatinine clearance measured creatinine clearance (CrCl) ≥50 mL/min as calculated by either the Cockcroft-Gault method, a 24-hour urine test or another validated test as per local practice (confirmation of creatinine clearance is only required when creatinine is >1.5 x institutional ULN)

    Cockcroft-Gault equation for estimated CrCL:

    CrCl (glomerular filtration rate [GFR]) = (140-age) x (weight/kg) x Fa (72 x serum creatinine mg/dL)

    1. where F= 0.85 for females and F=1 for males - Participants must have measurable disease by RECIST v. 1.1 criteria and be willing to undergo a pre-treatment and on-treatment tumor biopsy. The biopsy requirement can be waived only with approval from the sponsor-investigator.
    • For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.

    • Patient has read and understands the informed consent form (ICF) and has been given written ICF prior to any study procedures which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

    • Female patients who are not of child-bearing potential* and women of childbearing potential who agree to use adequate contraceptive measures from 2 weeks prior to the study and 5x half-lives of adavosertib + 6 months after study treatment discontinuation, who are not breastfeeding, and who have a negative serum or urine pregnancy test within 7 days prior to the start of study treatment.

    • Evidence of non-childbearing status, defined as below:

    -- Women who are surgically sterile (i.e., have undergone bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy).

    -- Age ≥50 years with any one or more of the conditions below:

    • Amenorrheic for 12 months or more following cessation of all hormonal replacement therapy

    • Had radiation-induced menopause with last menses >1 year ago

    • Had chemotherapy-induced menopause with last menses >1 year ago

    • Age <50 if amenorrhoeic for 12 months or more following cessation of all hormonal replacement therapy and if luteinizing hormone and follicle-stimulating hormone levels are in the post-menopausal range per institutional standards of practice.

    • Male patients should be willing to abstain or use barrier contraception (i.e., condoms) for the duration of the study drug exposure and for 5x half-lives of adavosertib + 3 months after study treatment discontinuation.

    • Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.

    Exclusion Criteria:
    • Patients who have previously received adavosertib are not eligible.

    • Use of an anti-cancer treatment drug ≤ 21 days or 5 half-lives (whichever is shorter) prior to the first dose of adavosertib (AZD1775).

    • Any prior palliative radiation must have been completed at least 7 days prior to the first dose of adavosertib, and patient must have recovered from any acute adverse effects, that the treating investigator thinks could impair the tolerance of the study drugs, prior to the start of study treatment.

    • Participants who have undergone major surgical procedures ≤ 28 days, or minor surgical procedures ≤ 7 days, of the first dose of adavosertib. No waiting period is required following port-a-cath or other central venous access placement.

    • Presence of CTCAE v5.0 Grade >1 toxicity from prior therapy (except alopecia, anorexia or CTCAE grade 2 peripheral neuropathy).

    • Patient is unable to swallow oral medications. Note: Patient may not have a percutaneous endoscopic gastrostomy (PEG) tube or be receiving total parenteral nutrition (TPN).

    • Participants with known malignant central nervous system (CNS) disease other than neurologically stable, treated brain metastases - defined as metastasis having no evidence of progression or hemorrhage for at least 2 weeks after the completion of treatment (including brain radiotherapy). Must be off any systemic corticosteroids for the treatment of brain metastases for at least 14 days prior to enrollment.

    • Participants receiving any medications or substances that are known to be moderate to strong inhibitors or inducers of CYP3A4 and which cannot be discontinued at least 2 weeks prior to the first dose of adavosertib are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product. Refer to Protocol Section 5 for information on prohibited concomitant medications.

    • Use of herbal medications or supplements within 7 days prior to the first dose of adavosertib.

    • History of hypersensitivity to compounds of similar chemical or biologic composition to gemcitabine or adavosertib.

    • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or psychiatric illness/social situations that would limit compliance with study requirements.

    • Known HIV-positive participants are ineligible because these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy.

    • Participants with a clinically significant gastrointestinal disorder that in the opinion of the treating investigator could impact the absorption of the study drugs, including but not limited to refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of adavosertib.

    • Participants with a history of a clinically relevant second primary malignancy within the past 2 years. Exceptions include: resected basal and squamous cell carcinomas of the skin and completely resected carcinoma in situ of any type.

    • Pregnant or lactating women are excluded from this study because gemcitabine/adavosertib are anti-cancer agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with gemcitabine/adavosertib, breastfeeding should be discontinued if the mother is treated with gemcitabine/adavosertib.

    • Any of the following cardiac diseases currently or within 6 months of the first dose of adavosertib:

    -- Unstable angina pectoris

    -- Acute myocardial infarction

    -- Congestive heart failure ≥ Class 2 (as defined by New York Heart Association (NYHA))

    -- Conduction abnormality not controlled with pacemaker or medication

    • Significant ventricular or supraventricular arrhythmias (patients with chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible)

    • History of Torsades de pointes unless all risk factors that contributed to Torsades have been corrected.

    • Participants ECG must not meet the following criteria:

    • Resting corrected QTc interval using the Fridericia formula (QTcF) >480 msec (as calculated per institutional standards) (Note: if one ECG performed as screening demonstrates a QTcF > 480 msec, then a mean QTcF of ≤ 480 msec obtained from 3 ECGs 2-5 minutes apart, is required at study entry for the participant to be considered eligible)

    • congenital long QT syndrome

    Contacts and Locations


    No locations specified.

    Sponsors and Collaborators

    • James Cleary, MD, PhD
    • AstraZeneca
    • Lustgarten Foundation
    • Stand Up To Cancer


    • Principal Investigator: James Cleary, MD, PhD, Dana-Farber Cancer Institute

    Study Documents (Full-Text)

    None provided.

    More Information


    None provided.
    Responsible Party:
    James Cleary, MD, PhD, Principal Investigator, Dana-Farber Cancer Institute Identifier:
    Other Study ID Numbers:
    • 21-620
    First Posted:
    Jan 27, 2022
    Last Update Posted:
    Jun 14, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Plan to Share IPD:
    Studies a U.S. FDA-regulated Drug Product:
    Studies a U.S. FDA-regulated Device Product:
    Keywords provided by James Cleary, MD, PhD, Principal Investigator, Dana-Farber Cancer Institute
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 14, 2022